A Statistical Assessment of QT Data Following Placebo and Moxifloxacin Dosing in Thorough QT Studies

@article{Stylianou2008ASA,
  title={A Statistical Assessment of QT Data Following Placebo and Moxifloxacin Dosing in Thorough QT Studies},
  author={Anastasia Stylianou and James H. Roger and Kimberley Stephens},
  journal={Journal of Biopharmaceutical Statistics},
  year={2008},
  volume={18},
  pages={502 - 516}
}
The ICH guidelines indicate that a single “thorough QT study” should be conducted to evaluate the effects of new drugs on cardiac repolarization. A positive control, such as moxifloxacin, is required to be assessed as part of the thorough QT study to validate the assay sensitivity of each study. In order to better understand the effect of moxifloxacin, a meta-analysis of nine thorough QT studies has been undertaken to assess the overall moxifloxacin effect. The data was analyzed using a… 

Statistical Characteristics of Moxifloxacin-Induced QTc Effect

TLDR
It is confirmed that the maximum moxifloxacin effect occurs in the time window between 1 and 4 h post dose, and the variability of the data as well as correlations between time points and between regimens are investigated.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects

AIMS This study was designed as a thorough QT (TQT) study to evaluate the effects of fluticasone furoate(FF)/vilanterol (VI) in healthy subjects. Supportive data from a TQT study conducted with FF

Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double‐blind, placebo‐, and active‐controlled thorough QT study

Prolongation of the QT interval has been observed with ondansetron and other members of the 5‐HT3 antagonist class. This is the first thorough QTc study of ondansetron conducted in accordance with

Further Discussion on the Design and Analysis of Thorough QTc Clinical Trials: Guest Editors' Notes

TLDR
The findings of this article provide information on the correlations assumed in sample size determination and multiple comparison adjustment when assessing assay sensitivity in TQT studies and the various correction methods through the expectation of the estimates.

Electrocardiographic Safety of Cangrelor, a New Intravenous Antiplatelet Agent: A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Thorough QT Study

TLDR
This thorough QT study demonstrated that therapeutic and supratherapeutic cangrelor doses do not adversely affect cardiac repolarization in normal volunteers.

A Randomized, Placebo‐ and Positive‐Controlled, Single‐Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects

TLDR
The results suggest that 500 mg daprodustat was not well tolerated; however, dapRodustat at 75 mg was generally well tolerated.

Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review

TLDR
Patients must be thoroughly assessed prior to the use of moxifloxacin and high-risk patients must be identified using risk assessment tools to ensure safe use and to safeguard patients’ health.

Statistical Evaluation of QT/QTc Interval Prolongation

TLDR
The CQT approach has been adopted by ICH E14 R3 as an acceptable alternative to TQT for the evaluation of QT prolongation risk and an alternative to concentration–QTc analysis is discussed.

Circadian Variation in QT Interval Demonstrating Assay Sensitivity in a Phase 1 Clinical Trial

TLDR
By recording sufficient ECGs throughout the day, circadian variation in QT interval has the potential to allow the detection of changes of more than 5 ms in phase 1 clinical trials and to obviate the need to include a positive control.

References

SHOWING 1-6 OF 6 REFERENCES

Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team

TLDR
It is recommended that the statistical rigor of the International Conference on Harmonisation guidance currently in development for clinical assessment be enhanced and that further research be conducted in the choice of endpoints, testing of hypotheses, and interpretation of QT and QTc data.

Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies

TLDR
Methods of analysis and statistical inference are developed for the QTc end points considered and consideration of the statistical properties of various end points proposed for measurement is considered.

Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline

TLDR
The studies described in S7B and E14 will contribute to a better understanding of the link between nonclinical assays and QT prolongation in humans and how predictive a negative thorough QT study result is for proarrhythmic risk in patients.

An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)

Generalized Latent Variable Modeling: Multilevel,Longitudinal, and Structural Equation Models

TLDR
To fully grasp some of the more complex aspects of sensitivity analysis, additional references are needed to supplement this text, and the technical material seemed overly complicated and lacking sufficient explanation.

The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. ICH Harmonized Tripartite Guideline

  • 2005